Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies.
Hyperuricemia is a common manifestation of lymphoid malignancies at diagnosis or after the start of chemotherapy. When accompanied by other metabolic abnormalities and/or organ failure, hyperuricemia may be a manifestation of tumor lysis syndrome (TLS). Patients at particularly high risk of such complications include those with acute lymphoblastic leukemia and advanced stage non-Hodgkin's lymphoma. Conventional measures to prevent hyperuricemia and TLS are comprised of hydration, alkalinization of body fluids, and administration of allopurinol. Although these measures are usually effective in preventing or managing hyperuricemia, approximately 20% of patients at high risk of TLS require dialysis, and many cannot receive chemotherapy as planned. Rasburicase, a recombinant form of the enzyme urate oxidase, has recently become available and may further reduce the morbidity of hyperuricemia and TLS. In this review, we provide an overview of hyperuricemia and TLS and discuss the impact of rasburicase in the overall management of these complications.
Ribeiro
Raul C
RC
The Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105-2794, USA. raul.ribeiro@stjude.org
Pui
Ching-Hon
CH
D002986:Clinical Trials as Topic; D006801:Humans; D033461:Hyperuricemia / Q000209:etiology / Q000517:prevention & control*; D008223:Lymphoma / Q000150:complications*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012307:Risk Factors; D015275:Tumor Lysis Syndrome / Q000209:etiology / Q000517:prevention & control*; D014503:Urate Oxidase / Q000627:therapeutic use*
D011994:Recombinant Proteins; C469709:rasburicase; D014503:Urate Oxidase